skip to main content

Oligoarticular JIA — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardPaediatric rheumatologyOligoarticular JIASCE Rheumatology

A child with JIA-associated anterior uveitis remains active despite topical glucocorticoid and methotrexate. What systemic escalation is best supported?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Add adalimumab through coordinated paediatric rheumatology and ophthalmology care

Persistent JIA uveitis threatens vision and requires coordinated systemic treatment. Adalimumab has evidence for methotrexate-refractory disease; etanercept is less effective for uveitis, and biologic combination therapy is unsafe.

Reference: NHS England: adalimumab for children with severe refractory uveitis (Published November 2015; updated January 2018): https://www.england.nhs.uk/2015/11/adalimumab-child/; NHS England: biologic therapies for juvenile idiopathic arthritis (Published July 2015; updated April 2026): https://www.england.nhs.uk/publication/biologic-therapies-for-the-treatment-of-juvenile-idiopathic-arthritis-jia/